VCM
NBIX icon

Voleon Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Voleon Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-7,638
Closed -$1.01M – 873
2026
Q1 		$1.01M Buy
7,638
+1,137
+17% +$151K 0.02% 438
2025
Q4 		$922K Sell
6,501
-11,791
-64% -$1.71M 0.02% 456
2025
Q3 		$2.57M Buy
+18,292
New +$2.48M 0.06% 286

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Voleon Capital Management's NBIX Position: Q2 2026 in Review

Voleon Capital Management sold out of Neurocrine Biosciences (NBIX) in Q2 2026, closing a stake of 7,638 shares — an estimated $1.01M sold.

Voleon Capital Management first reported a position in NBIX in Q3 2025 and held it in 3 quarters. The position peaked at $2.57M in Q3 2025. 778 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Voleon Capital Management reported no remaining Neurocrine Biosciences position as of Q2 2026 after selling out during the quarter.
  • Voleon Capital Management sold 7,638 Neurocrine Biosciences shares in Q2 2026, an estimated $1.01M.
  • Voleon Capital Management first reported a position in Neurocrine Biosciences in Q3 2025 and held it in 3 quarters.
  • Voleon Capital Management's Neurocrine Biosciences position peaked at $2.57M in Q3 2025.
  • 778 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Voleon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.